uniQure « Terug naar discussie overzicht

Analisten over UniQure

243 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 » | Laatste

Omlaag ↓

flosz 16 juni 2015 15:27

quote:
invoorentegenspoed schreef op 16 juni 2015 15:20:
Van Zacks bevinding vind ik niets terug waarop ik mijn visie zou kunnen finetunen.

Meer via www.zacks.com/registration/marketing/...
Maar ik dacht: laMarLekkerZitteDanNieDan.....

[verwijderd] 17 juni 2015 21:04

and now something completely different?

finance.yahoo.com/news/uniqure-n-v-qu...

Can uniQure N.V. (QURE) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks By Zacks Equity Research
6 hours ago

uniQure N.V. (QURE) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on QURE’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that uniQure could be a solid choice for investors.

Current Quarter Estimates for QURE
Related Quotes

QURE30.81+0.79%

uniQure N.V.
Watchlist
30.81+0.24(0.79%)
NASDAQ1:59PM EST

Can uniQure N.V. (QURE) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape Zacks 6 hrs ago
UniQure a Potential Takeout Candidate Barrons.com q 13 days ago

More

In the past 30 days, 1 estimate has gone higher for uniQure while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 63 cents a share 30 days ago, to a loss of 7 cents today.

Current Year Estimates for QURE

Meanwhile, uniQure’s current year figures are also looking quite promising. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $2.47 per share 30 days ago to a loss of $2.04 per share today.

Bottom Line

The stock has also started to move higher lately, adding 16.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UNIQURE BV (QURE): Free Stock Analysis Report

flosz 22 juni 2015 15:38

Oppenheimer.
twitter.com/jayabacus/status/61296296...

Bijlage:

flosz 23 juni 2015 10:21

Zacks Short Term Rating on uniQure N.V.
uniQure N.V. (NASDAQ:QURE) remains a strong buy in the latest set of rankings. The shares has received an average rating of 1 by 8 analysts. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation is Neutral on the company. uniQure N.V. (NASDAQ:QURE): The mean short term price target for uniQure N.V. (NASDAQ:QURE) has been established at $42.88 per share. The higher price target estimate is at $50 and the lower price target estimate is expected at $38 according to 8 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $4.91

uniQure N.V. (NASDAQ:QURE) rose 5.86% or 1.84 points on Monday and made its way into the gainers of the day. After trading began at $31.52 the stock was seen hitting $33.93 as a peak level and $31.52 as the lowest level. The stock ended up at $33.25. The daily volume was measured at 360,809 shares. The 52-week high of the share price is $35.5 and the 52-week low is $9. The company has a market cap of $713 million.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Companys first product is Glybera, for the treatment of lipoprotein lipase deficiency (LPLD). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

tinyurl.com/on3swsk

Oppenheimer Reaffirms Outperform Rating for Uniqure NV (QURE)

Uniqure NV (NASDAQ:QURE)‘s stock had its “outperform” rating reissued by equities researchers at Oppenheimer in a research report issued on Monday. They currently have a $47.00 price target on the stock. Oppenheimer’s price target points to a potential upside of 41.35% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Zacksdowngraded shares of Uniqure NV from a “hold” rating to a “sell” rating in a research note on Monday, June 15th. Analysts at Piper Jaffray set a $40.00 price target on shares of Uniqure NV and gave the company a “buy” rating in a research note on Friday, June 12th. Analysts at Roth Capital reiterated a “buy” rating and set a $38.00 price target on shares of Uniqure NV in a research note on Monday, June 8th. Finally, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Uniqure NV in a research note on Saturday, May 9th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $43.13.

Shares of Uniqure NV (NASDAQ:QURE) traded up 5.86% during mid-day trading on Monday, hitting $33.25. 360,809 shares of the company’s stock traded hands. Uniqure NV has a 52 week low of $9.00 and a 52 week high of $35.50. The stock has a 50-day moving average of $28. and a 200-day moving average of $23.. The company’s market cap is $612.73 million.

www.dakotafinancialnews.com/oppenheim...

flosz 23 juni 2015 10:35

StockReversals: $QURE our original early February 2015 report on Uniqure at $19.70 t.co/MQ7tyws9c4
twitter.com/stockreversals/status/613...

Tex Mex 15 juli 2015 13:52

uniQure komt steeds meer in the picture, langzaam maar zeker. Geduld, geduld.

Uniqure NV logoCowen and Company began coverage on shares of Uniqure NV (NASDAQ:QURE) in a research note issued on Wednesday, AnalystRatings.Net reports. The firm set an “outperform” rating on the stock.

QURE has been the subject of a number of other recent research reports. Analysts at Roth Capital reiterated a “buy” rating and set a $38.00 price target on shares of Uniqure NV in a research note on Monday, July 6th. Analysts at Oppenheimer reiterated an “outperform” rating and set a $47.00 price target on shares of Uniqure NV in a research note on Monday, June 22nd. Analysts at Zacks downgraded shares of Uniqure NV from a “hold” rating to a “sell” rating in a research note on Monday, June 15th. Analysts at Piper Jaffray set a $40.00 price target on shares of Uniqure NV and gave the company a “buy” rating in a research note on Friday, June 12th. Finally, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Uniqure NV in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Uniqure NV currently has a consensus rating of “Buy” and an average target price of $43.13.

Shares of Uniqure NV (NASDAQ:QURE) opened at 27.98 on Wednesday. Uniqure NV has a one year low of $9.00 and a one year high of $35.50. The stock has a 50-day moving average of $29.18 and a 200-day moving average of $25.08. The company’s market cap is $515.62 million.

Uniqure NV (NASDAQ:QURE) last announced its earnings results on Thursday, June 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.13. The company had revenue of $1.17 million for the quarter, compared to the consensus estimate of $9.50 million. On average, analysts predict that Uniqure NV will post $-0.57 earnings per share for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company’s first product is Glybera, for the treatment of lipoprotein lipase deficiency (NASDAQ:QURE). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

www.streetinsider.com/dr/news.php?id=...

[verwijderd] 16 juli 2015 15:36

kijk, bij UniQure kunnen analisten zeggen wat ze willen en zie je niets gebeuren...bij ONCE vechten ze elkaar de tent uit bij een Motley Fool adviesje:

www.fool.com/investing/general/2015/0...

No. 2 Spark Therapeutics (NASDAQ:ONCE)
Although Spark Therapeutics doesn't have any products on the market, investors' hope that it can help ignite gene therapies has led to a market cap that's already north of $1.5 billion.

Because the company is expected to report phase 3 data for its SPK-RPE65 soon, investors should gain insight into whether that's an appropriate valuation shortly.

Spark Therapeutics' SPK-RPE65 studies are evaluating the gene-replacement injection in people with mutations to the RPE65 gene and, if trial results are positive, then the company could file for FDA approval by the end of this year. If that application results in an FDA green light, then SPK-RPE65 could bring new hope to as many as 3,500 people with this type of inherited retinal dystrophy in the U.S. and Europe.

SPK-RPE65's success could also help validate Spark Therapeutics' SPK-CHM, a therapy that relies on similar technology that could help restore vision in up to 12,500 patients. Since results for SPK-RPE65 could be a binary event, I wouldn't be shocked if shares head significantly higher or lower following the release of this data, and for that reason, investors should approach this one cautiously.

flosz 28 juli 2015 16:10

Roth $QURE GT for Parkinson's Shaping Up to Be
an Intriguing Datapoint twitter.com/dougheuringaria/status/62...

Bijlage:

Fartknock 7 augustus 2015 16:40

Investment analysts at WallachBeth Capital began coverage on shares of Uniqure NV (NASDAQ:QURE) in a research note issued to investors on Friday, Analyst Ratings.Net reports. The firm set a “buy” rating and a $35.00 price target on the stock. WallachBeth Capital’s target price would indicate a potential upside of 41.47% from the stock’s previous close.

Several other research firms also recently commented on QURE. Piper Jaffray set a $40.00 price target on Uniqure NV and gave the company a “buy” rating in a report on Friday, June 12th. Zacks downgraded Uniqure NV from a “hold” rating to a “sell” rating in a report on Monday, June 15th. Oppenheimer reissued an “outperform” rating and issued a $47.00 price target on shares of Uniqure NV in a research report on Monday, June 22nd. Cowen and Company started coverage on Uniqure NV in a research report on Wednesday, July 15th. They issued an “outperform” rating on the stock. Finally, Roth Capital reissued a “buy” rating and set a $38.00 price target on shares of Uniqure NV in a report on Thursday, July 16th. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $42.22.

Shares of Uniqure NV (NASDAQ:QURE) opened at 24.74 on Friday. The company’s market cap is $455.91 million. The company’s 50 day moving average price is $27.62 and its 200 day moving average price is $25.99. Uniqure NV has a 12 month low of $9.00 and a 12 month high of $35.50.

Uniqure NV (NASDAQ:QURE) last issued its quarterly earnings results on Thursday, June 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.13. The firm had revenue of $1.17 million for the quarter, compared to the consensus estimate of $9.50 million. On average, equities analysts expect that Uniqure NV will post ($0.92) EPS for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company’s first product is Glybera, for the treatment of lipoprotein lipase deficiency (NASDAQ:QURE). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

www.dakotafinancialnews.com/uniqure-n...

[verwijderd] 8 augustus 2015 01:04

"Shares of Uniqure NV (NASDAQ:QURE) opened at 24.74 on Friday. The company’s market cap is $455.91 million. The company’s 50 day moving average price is $27.62 and its 200 day moving average price is $25.99. Uniqure NV has a 12 month low of $9.00 and a 12 month high of $35.50. "

die lui mogen hun huiswerk nog eens goed doen...marketcap 445,91mln???

En geen woord over de BMS-deal?

flosz 10 augustus 2015 17:26

Roth twitter.com/jayabacus/status/63075270...

Bijlage:

flosz 27 augustus 2015 21:46

Stock analysts at Chardan Capital dropped their price target on shares of Uniqure NV (NASDAQ:QURE) from $40.00 to $35.00 in a report released on Thursday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s price objective suggests a potential upside of 42.22%

Analyst Gbola Amusa noted that the lowered price target stems from (1) uncertainty for Glybera in the US, which now leads us, out of conservatism, to remove Glybera US completely from our model ($3) and (2) our view of an increasing equity risk premium in the markets ($2). Importantly, UniQure confirmed upcoming catalysts on the important hemophilia B program (77% of our price target) and provided increasing visibility on what we consider upside options in the Sanfilippo B and Parkinson's disease programs. We thus reaffirm our Buy rating, anticipating upside from here through end 2016 on upcoming catalysts for AMT-110 (Sanfilippo B) and AMT-060 (hemophilia B).

twitter.com/tickerreport/status/63692...

flosz 28 augustus 2015 15:47

Leerink: twitter.com/dougheuringaria/status/63...

Bijlage:

flosz 28 augustus 2015 16:01

Oppy: twitter.com/dougheuringaria/status/63...

Bijlage:

flosz 28 augustus 2015 18:27

uniQure (QURE) is Reiterated by WallachBeth to Buy according to the research report released to the investors. The Brokerage Firm has Lowered the Price Target of the company shares to $33 from a previous price target of $35 . The shares recommendation by the Brokerage Firm was released on Aug-28-2015.

uniQure N.V. (NASDAQ:QURE): 9 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $42 in uniQure N.V. (NASDAQ:QURE). However, the stock price could fluctuate by $ 5.29 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $50 price target with the lower price estimate is calculated at $35

www.moneyflowindex.org/uniqure-qure-i...

flosz 8 september 2015 15:55

Roth $QURE Risk / Reward Attractive Heading into
the Sanfilippo Abstract
The first-in-human, gene-therapy abstract available on Sept 21st.
twitter.com/tgtxdough/status/64119883...

Stabilization/durability neurologic function drive $QURE $30’s, but data highlighting reversal existing pathol- ogy implies$40+

flosz 21 september 2015 09:09

Verdwenen tweet.....
www.twitlonger.com/show/_1sngedp

Cowen $QURE Sanfilippo B.

Bijlage:

flosz 21 september 2015 09:10

+
Laatste regels....

Bijlage:

flosz 21 september 2015 09:45

Linkjes
Cowen, Piper and Roth.

twitter.com/el_sequenco/status/645845...
twitter.com/el_sequenco/status/645846...
twitter.com/el_sequenco/status/645846...

Bijlage:

flosz 21 september 2015 09:46

Bijlage:

243 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 882,63 +12,36 +1,42% 26 apr


Germany40^	18.177,90	+1,45%
BEL 20	3.874,87	+0,44%
Europe50^	5.011,70	+0,10%
US30^	38.211,61	0,00%
Nasd100^	17.698,09	0,00%
US500^	5.095,29	0,00%
Japan225^	38.345,55	0,00%
Gold spot	2.337,95	0,00%
EUR/USD	1,0693	-0,34%
WTI	83,64	0,00%